Cargando…

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate(TM) Trial

PURPOSE: The first report from the open-label substudy of the phase III iNNOVATE study (PCYC-1127; NCT02165397) demonstrated that single-agent ibrutinib was efficacious and well tolerated in patients with heavily pretreated, rituximab-refractory Waldenström macroglobulinemia. Results from the final...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trotman, Judith, Buske, Christian, Tedeschi, Alessandra, Matous, Jeffrey V., MacDonald, David, Tam, Constantine S., Tournilhac, Olivier, Ma, Shuo, Treon, Steven P., Oriol, Albert, Ping, Jerry, Briso, Eva M., Arango-Hisijara, Israel, Dimopoulos, Meletios A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Clinical Trials: Targeted Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401517/ https://www.ncbi.nlm.nih.gov/pubmed/34380643 http://dx.doi.org/10.1158/1078-0432.CCR-21-1497

Ejemplares similares

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
por: Buske, Christian, et al.
Publicado: (2022)

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
por: Papanota, Aristea-Maria, et al.
Publicado: (2019)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

P1679: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN TRIAL LONG-TERM FOLLOW-UP
por: Tedeschi, Alessandra, et al.
Publicado: (2023)

A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
por: Castillo, Jorge J., et al.
Publicado: (2022)

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic
por: Talaulikar, Dipti, et al.
Publicado: (2020)

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
por: An, Gang, et al.
Publicado: (2021)

Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
por: Dogliotti, Irene, et al.
Publicado: (2022)

Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
por: Büyükkurt, Nurhilal, et al.
Publicado: (2023)

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
por: Gustine, Joshua N., et al.
Publicado: (2021)

How to manage Waldenstrom's macroglobulinemia
por: Buske, C, et al.
Publicado: (2013)

Genomic landscape of Waldenström's macroglobulinemia
por: Treon, Steven P., et al.
Publicado: (2019)

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2021)

Treatment options for relapsed Waldenström's Macroglobulinemia
por: Grunenberg, Alexander, et al.
Publicado: (2019)

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia
por: Gavriatopoulou, Maria, et al.
Publicado: (2017)

Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials
por: Castillo, Jorge J., et al.
Publicado: (2020)

Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy
por: Aiello, Andrea, et al.
Publicado: (2017)

PB2074: IBRUTINIB AS A PROMISING TREATMENT FOR WALDENSTRÖM MACROGLOBULINEMIA
por: Ilhan, O., et al.
Publicado: (2022)

Waldenstrom’s Macroglobulinemia: An Update
por: Mazzucchelli, Maddalena, et al.
Publicado: (2018)

Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2021)

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia
por: Treon, Steven P., et al.
Publicado: (2021)

P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
por: Dimopoulos, M., et al.
Publicado: (2022)

Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
por: Castillo, Jorge J., et al.
Publicado: (2022)

HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom's Macroglobulinemia
por: Wallace, Mark R.
Publicado: (2020)

Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia
por: Poza, María, et al.
Publicado: (2021)

Ventricular Tachycardia Storm in a Patient Treated With Ibrutinib for Waldenstrom Macroglobulinemia
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

PB2081: TREATMENT PERSISTENCE AND ADHERENCE TO IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA: A GERMAN CLAIMS DATA ANALYSIS
por: Buske, C., et al.
Publicado: (2022)

SARS-CoV-2 Infection in Patients With Waldenström’s Macroglobulinemia: A Multicenter International Cohort Study
por: Defrancesco, Irene, et al.
Publicado: (2023)

Waldenström's macroglobulinemia front line treatment
por: Tedeschi, Alessandra, et al.
Publicado: (2019)

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
por: Allan, John N., et al.
Publicado: (2023)

1130. Low Risk of Pneumocystis jiroveci Pneumonia in Patients With Waldenstrom’s Macroglobulinemia on Ibrutinib
por: Kusztos, Amanda E, et al.
Publicado: (2018)

Successful Management of Ibrutinib-Induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia
por: Erçalışkan, Abdülkadir, et al.
Publicado: (2022)

A prognostic index predicting survival in transformed Waldenström macroglobulinemia
por: Durot, Eric, et al.
Publicado: (2020)

Venetoclax in Previously Treated Waldenström Macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2022)

Pseudohyperphosphatemia in Waldenstrom's Macroglobulinemia
por: Amalnath, S. D., et al.
Publicado: (2013)

Waldenstrom Macroglobulinemia Manifesting as Acute Kidney Injury and Bing-Neel Syndrome With Excellent Response to Ibrutinib
por: Jafri, Hassaan, et al.
Publicado: (2021)

High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia
por: Durot, Eric, et al.
Publicado: (2022)

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
por: Terpos, E., et al.
Publicado: (2023)

Waldenstrom's macroglobulinemia associated with eosinophilia
por: You, Eunkyoung, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lc88t1fr8rvueukb5nr0ki3b4u